TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07090785: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4088044 in Healthy Participants.

Sponsor: Eli Lilly and Company · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 104 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$3,837,920

Rescue Site Savings

+$2,528,512

Unlock Full NCT07090785 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07090785 Rescue Dossier →